---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Clinical presentation - signs and symptoms. Topics: Asymptomatic presentation: elevated blood pressure without signs or symptoms; Target organ damage: heart, vasculature, kidneys, brain, and retina; Acute presentation: hypertensive emergency; Sleep-related symptoms: obstructive sleep apnea; 3 further topics. 7 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Asymptomatic presentation: elevated blood pressure without signs or symptoms

> “Most people with high blood pressure, also called hypertension, have no signs or symptoms.”
> “High blood pressure usually has no signs or symptoms, so many people do not know they have it.”
> “The only way to know if you have high blood pressure is to measure your blood pressure regularly.”

Source: [CDC About High Blood Pressure (2026)](https://www.cdc.gov/high-blood-pressure/about/index.html)

> “about 1 in 6 adults with high blood pressure is unaware of it and would not report having it”

Source: [CDC High Blood Pressure Facts (2026)](https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/index.html)

<a id="topic-2.2.1.6-2"></a>

### Target organ damage: heart, vasculature, kidneys, brain, and retina

> “Hypertension-related target organ damage describes adverse structural or functional changes in major organ systems, including the heart, vasculature, kidneys, brain, and retina due to hypertension.”
> “Common forms of target organ damage include left ventricular hypertrophy, HF, subclinical and clinical atherosclerosis, CKD (ie, reduced eGFR or albuminuria), and cerebrovascular disease (eg, stroke, dementia, retinopathy).”
> “longitudinal data indicate at least 1 form of hypertension-related target organ damage is present in >50% of individuals with hypertension.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “The former group was younger, more frequently men, with a longer duration of hypertension and a worse cardiovascular risk profile.”
> “The group included larger proportions of smokers, diabetics, target organ damage (including left ventricular hypertrophy, impaired renal function, and microalbuminuria), and documented cardiovascular disease.”

Source: [de la Sierra et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21444835/)

<a id="topic-2.2.1.6-3"></a>

### Acute presentation: hypertensive emergency

> “Hypertensive emergencies are defined as severe elevations in BP (>180/120 mm Hg) associated with evidence of acute target organ damage.”
> “Patients with hypertensive emergencies experience a high in-hospital mortality rate of 10% with a 1-year cardiovascular morbidity and mortality rate of 20% to 30%.”
> “Common forms of acute hypertension-related target organ damage include acute HF/pulmonary edema, neurologic disorders (encephalopathy, ICH, acute ischemic stroke), and AKI, with aortic dissection the least common presentation.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.6-4"></a>

### Sleep-related symptoms: obstructive sleep apnea

> “Very high proportions (60%−84%) of individuals with RH have sleep apnea.”
> “clinicians should vigorously screen such patients for symptoms of OSA (loud snoring, frequent nocturnal arousals, witnessed apnea, and excessive daytime sleepiness) and have a low threshold for referral for definitive evaluation and treatment.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “Snoring, choking, gasping during sleep; daytime sleepiness; resistant hypertension”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.6-5"></a>

### Electrolyte signs: hypokalemia in primary aldosteronism

> “Spontaneous hypokalemia is present only in 20% to 50% of patients with primary aldosteronism”
> “Although the increased potassium excretion, if prolonged and severe, may cause hypokalemia, hypokalemia is absent in the majority of cases in whom normokalemia has a low negative predictive value for the diagnosis of primary aldosteronism.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “On the basis of salt suppression tests, 182 (11.3%) patients had primary hyperaldosteronism, and response to spironolactone treatment further confirmed this diagnosis.”
> “Hypokalaemia was seen only in 83 patients with primary hyperaldosteronism (45.6%).”

Source: [Douma et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18539224/)

<a id="topic-2.2.1.6-6"></a>

### Circadian blood pressure pattern: nocturnal nondipping

> “The normal nocturnal decline in BP is also attenuated in a high proportion (43%−65%) of individuals with RH.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “Moreover, true resistant hypertensives exhibited in a greater proportion a riser pattern (22% versus 18%; P<0.001).”

Source: [de la Sierra et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21444835/)

<a id="topic-2.2.1.6-7"></a>

### Paroxysmal symptoms: pheochromocytoma and paraganglioma

> “The prevalence is likely higher in patients referred for RH (eg, up to 4%).”
> “Symptoms include paroxysmal hypertension (which may be sustained in up to 50% of those with high norepinephrine production or orthostatic in epinephrine-predominant tumors) associated with headache, palpitations, pallor, and piloerection”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
